Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
What 503A Compounding Pharmacies Currently Cannot Make These widely used clinical peptides are not eligible for 503A compounding under current rules: BPC-157 (Body Protective Compound, used for tendon, ligament, and gut-lining repair) TB-500 / Thymosin Beta-4 fragment (recovery and inflammation modulation) CJC-1295 (GHRH analog, used for growth hormone optimization) Ipamorelin (selective GH secretagogue) MOTS-c (mitochondrial-derived peptide, metabolic and longevity research) Epithalon (Epitalon) (telomere-supporting longevity peptide) Semax (cognitive and neuroprotective peptide) GHK-Cu (copper tripeptide for skin and tissue regeneration) AOD-9604 (modified fragment of growth hormone, studied for fat metabolism) These peptides are widely studied
190 These studies suggest that promoting ferroptosis is a promising strategy to overcome drug resistance in colon cancer patients
BPC-157 sits at the intersection of several booming markets: Early adopters and brands offering oral BPC-157 capsules will likely capitalize on this wave of consumer interest
Get 20% off your first peptide order Join for early access when the service launches mL mg/mL Reconstituting your vial Reconstitution is adding liquid, almost always bacteriostatic water, to a freeze-dried (lyophilized) peptide so you can measure and inject it
doi: 10.3389/fnut.2023.1015046 Received 09 August 2022 Accepted 16 February 2023 Published 06 March 2023 Volume 10 - 2023 Edited by Domenico Sergi, University of Ferrara, Italy Reviewed by Tianlin Gao, Qingdao University, China
US$ 25.07
US$ 22.71
US$ 28.14
US$ 29.25
